The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cholera vaccines market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cholera is an intestinal disease caused by bacterial infections that spread through contaminated food and water. It leads to severe diarrhea, dehydration, abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is presently a global threat to public health, which can be prevented through the vaccine. The cholera vaccine exposes a small dose of live cholera bacteria in the body that helps develop immunity against the disease. It can be given orally or injected intradermally or intramuscularly in the body.
The growing prevalence of cholera on account of poor hygiene and sanitation represents one of the major factors driving the market. In addition, there is a rise in the use of contaminated water for agriculture and olericulture across the globe. This, along with the increasing consumption of street and fast food due to the hectic lifestyles of individuals, is propelling the growth of the market. Moreover, there is a considerable rise in water pollution on account of sewage and factory wastes getting discharged into lakes and rivers. As a result, people are consuming contaminated seafood worldwide, which, in turn, is resulting in the spread of cholera. Additionally, rising awareness about cholera through initiatives of non-governmental organizations (NGOs), along with numerous immunization programs introduced by governments of several countries to reduce vaccine-preventable diseases, is positively influencing the market. Furthermore, key market players are extensively investing in research and development (R&D) activities to provide more efficient and cost-effective cholera vaccines, which is projected to propel the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cholera vaccines market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, product and end user.
Breakup by Vaccine Type:
Breakup by Product:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.
|Base Year of the Analysis||2021|
|Segment Coverage||Vaccine Type, Product, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at